Plus Therapeutics Rebrands as Cerenome, Affirms 2026 Milestones
Event summary
- Plus Therapeutics rebrands to Cerenome, trading under new Nasdaq ticker CNSY effective August 3, 2026.
- Company affirms 2026 guidance on key milestones, including commercial progress for CNSide Diagnostics.
- REYOBIQ clinical trials advance: ReSPECT-LM Phase 2 trial nearing optimal dose determination, ReSPECT-GBM Phase 2 trial near full enrollment.
- CNSide commercial expansion reaches approximately 126 million covered lives with new payer agreements.
- AI strategy partnership with Ephemeral Technologies announced to support data infrastructure buildout.
The big picture
Cerenome's rebranding reflects its strategic shift toward an integrated CNS oncology platform, combining therapeutics, diagnostics, and advanced data analytics. The company's progress in clinical trials and commercial expansion positions it to capitalize on the growing demand for precision treatments in central nervous system cancers. The AI strategy aims to create a competitive edge through real-world evidence generation and partnership opportunities.
What we're watching
- Clinical Progress
- Whether REYOBIQ can achieve recommended Phase 2 dose by year-end and advance toward registration study.
- Commercial Scale
- The pace at which CNSide Diagnostics expands to over 150 million covered lives and increases test volume.
- AI Integration
- How the AI strategy partnership with Ephemeral Technologies will enhance data analytics and operational efficiency.
Related topics